Last reviewed · How we verify
Synera(TM)
Synera is a topical anesthetic patch that combines lidocaine and tetracaine to provide rapid local anesthesia through transdermal delivery.
Synera is a topical anesthetic patch that combines lidocaine and tetracaine to provide rapid local anesthesia through transdermal delivery. Used for Topical anesthesia for superficial venous access and dermatological procedures.
At a glance
| Generic name | Synera(TM) |
|---|---|
| Sponsor | IWK Health Centre |
| Drug class | Topical local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Synera uses heat-activated technology to enhance the penetration of lidocaine and tetracaine through the skin. The patch generates heat when activated, which increases blood flow and drug permeability, allowing the local anesthetics to reach deeper tissue layers and provide faster onset of anesthesia compared to non-heated patches.
Approved indications
- Topical anesthesia for superficial venous access and dermatological procedures
Common side effects
- Erythema at application site
- Edema at application site
- Skin irritation
- Blanching
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synera(TM) CI brief — competitive landscape report
- Synera(TM) updates RSS · CI watch RSS
- IWK Health Centre portfolio CI